Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Aragen Bioscience, Inc.. (9/9/15). "Press Release: Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology". Morgan Hill, CA.

Organisations Organisation Aragen Bioscience Inc.
  Group GVK Biosciences (Group)
  Organisation 2 ProteoNic Biotechnology B.V.
Products Product UNic™ expression technology
  Product 2 cell line development (recombinant protein production)
Index term Index term GVK Biosciences–ProteoNic: gene expression technology, 201509– license to use 2G UNic technology for cell line development to Aragen Bioscience
Persons Person Beske, Oren (Aragen Bioscience 201509 COO)
  Person 2 Schut, P. Victor (ProteoNic 201411 CBO before CEO)
     


Aragen Bioscience, Inc. (Aragen) announces that it has entered into an agreement with ProteoNic Biotechnology BV (ProteoNic) for the commercial use of ProteoNic’s 2G UNic™ recombinant protein production technology. Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods. In combination with the value added services offered by Aragen, access to the technology will allow Aragen’s clients to increase manufacturing efficiency and reduce cost of goods for recombinant biologicals.

ProteoNic’s proprietary second generation mammalian expression technology is based on the synergistic effect of novel genetic elements which exert a powerful positive effect on recombinant protein production levels as well as on stability of expression. The technology has been demonstrated to be broadly applicable to various protein targets, multiple host cell lines as well as selection systems. Importantly, it can be combined with most other production technologies for increased effectiveness.

“We have performed evaluations of ProteoNic’s 2G UNic™ technology for a number of products in stable and transient protein expression settings. To date, we have consistently obtained a significant increase in cell culture productivity. We believe that the combination of this technology and Aragen’s services will provide significant value to our current and future clients.” commented Oren Beske, Ph.D., Chief Operating Officer at Aragen Bioscience.

Victor Schut, Chief Business Officer at ProteoNic added, “Based on Aragen’s extensive client base and experience in cell line generation, this relationship will enable us to make available our technology more broadly than before, while maintaining the highest standards of execution. Companies outsourcing preclinical drug development to Aragen will now have access to ProteoNic’s technology for generating high performance cell lines.”

Under the terms of the agreement, Aragen will offer cell line development services including ProteoNic technology for production of biologicals for commercial use under a fee for service relationship. The ProteoNic technology is offered without a royalty.


About Aragen Bioscience

Aragen Bioscience, Inc. (Aragen, Morgan Hill, CA, USA) is a privately held contract research organization with offices and laboratories in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products.


About ProteoNic

ProteoNic Biotechnology BV (ProteoNic, Leiden, the Netherlands) is a privately held company with offices in Leiden, the Netherlands and Boston, USA. The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability. The company commercializes its proprietary 2G UNic™ technology through licensing and partnership arrangements.


Contacts

Aragen Bioscience
Oren Beske, Ph.D., COO
Phone: 408.779.1700
info@aragenbio.com

ProteoNic
Victor Schut, CBO
+31 71 523 1951
press@proteonic.nl

   
Record changed: 2016-01-10

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for GVK Biosciences (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top